title: Chimerism does not predict for outcome after alemtuzumab based conditioning.
authors.forename: L
authors.initials: L
authors.lastname: Michaelis
authors.forename: S
authors.initials: S
authors.lastname: Lin
authors.forename: L
authors.initials: L
authors.lastname: Joseph
authors.forename: A S
authors.initials: AS
authors.lastname: Artz
authors.forename: J
authors.initials: J
authors.lastname: Kline
authors.forename: D
authors.initials: D
authors.lastname: Pollyea
authors.forename: W
authors.initials: W
authors.lastname: Stock
authors.forename: E
authors.initials: E
authors.lastname: Rich
authors.forename: D
authors.initials: D
authors.lastname: Collins-Jones
authors.forename: B
authors.initials: B
authors.lastname: Casey
authors.forename: P
authors.initials: P
authors.lastname: Del Cerro
authors.forename: K
authors.initials: K
authors.lastname: van Besien
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D006086:Graft vs Host Disease / Q000517:prevention & control; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy; D006801:Humans; D033581:Stem Cell Transplantation; D018183:Transplantation Chimera / Q000276:immunology*; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab